The Rise of Modular Manufacturing: Scalable Solutions to Accelerate Novel Therapy Development
- Novel therapeutic development is focused on increasingly individualized solutions, requiring smaller, more customized batches of reagents and buffers to be used across the clinical pipeline as companies scale from research to process development and into commercialization.
- Existing bioprocessing infrastructure was not designed to manufacture these next-generation therapies, forcing the industry to look for research-and-clinical-grade reagent formulations that are easily customizable, scalable, and efficiently manufactured.
- Teknova has been able to leverage their modular manufacturing platform to help novel therapy developers across cell and gene therapy, mRNA, and next-generation antibodies (ADCs and multispecifics) accelerate their breakthroughs to get into the clinical faster.
- Find out more about what criteria novel therapy developers should be considering when evaluating reagent solutions.